Eton Pharmaceuticals, Inc. ETON Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eton Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eton Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization?
- Eton Pharmaceuticals, Inc. (ETON) reported operating lease right-of-use asset amortization of $9K in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Eton Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization decreased by 47.1% year-over-year, from $17K to $9K.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), Eton Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization has grown at a -10.8% compound annual growth rate (CAGR), from $62K to $44K.